CA2427809A1 - Enterotoxine nsp4 de rotavirus et ses methodes d'utilisation - Google Patents

Enterotoxine nsp4 de rotavirus et ses methodes d'utilisation Download PDF

Info

Publication number
CA2427809A1
CA2427809A1 CA002427809A CA2427809A CA2427809A1 CA 2427809 A1 CA2427809 A1 CA 2427809A1 CA 002427809 A CA002427809 A CA 002427809A CA 2427809 A CA2427809 A CA 2427809A CA 2427809 A1 CA2427809 A1 CA 2427809A1
Authority
CA
Canada
Prior art keywords
nsp4
peptide
nucleic acid
protein
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002427809A
Other languages
English (en)
Inventor
Mary K. Estes
Judith M. Ball
Peng Tian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/705,621 external-priority patent/US6673355B1/en
Application filed by Individual filed Critical Individual
Publication of CA2427809A1 publication Critical patent/CA2427809A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur la glycoprotéine non structurelle de Rotavirus, NSP4, laquelle remplit différentes fonctions dans le cycle de réplication des virus, notamment au cours de la morphogenèse virale. Plus précisément, la NSP4 est un récepteur intracellulaire qui intervient dans le développement d'une enveloppe membranaire transitoire pendant la phase de bourgeonnement de nouvelles particules sous-virales dans le réticulum endoplasmique (ER). Ladite invention porte sur la NSP4 et ses méthodes d'utilisation. Elle a plus particulièrement trait à l'utilisation de la NSP4 et de fragments de celle-ci (NSP4 114-135, NSP4 120-147, NSP4 112-174, ou NSP4 112-150) dans la prévention ou le traitement de maladies à Rotavirus.
CA002427809A 2000-11-03 2001-11-02 Enterotoxine nsp4 de rotavirus et ses methodes d'utilisation Abandoned CA2427809A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/705,621 US6673355B1 (en) 1995-06-14 2000-11-03 Rotavirus enterotoxin NSP4 and methods of using same
US09/705,621 2000-11-03
PCT/US2001/045255 WO2002036172A2 (fr) 2000-11-03 2001-11-02 Enterotoxine nsp4 de rotavirus et ses methodes d'utilisation

Publications (1)

Publication Number Publication Date
CA2427809A1 true CA2427809A1 (fr) 2002-05-10

Family

ID=24834264

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002427809A Abandoned CA2427809A1 (fr) 2000-11-03 2001-11-02 Enterotoxine nsp4 de rotavirus et ses methodes d'utilisation

Country Status (4)

Country Link
EP (1) EP1349571A4 (fr)
AU (1) AU2002220025A1 (fr)
CA (1) CA2427809A1 (fr)
WO (1) WO2002036172A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1576877A1 (fr) * 2004-03-04 2005-09-21 Bioprotein Technologies Production de protéines recombinantes de rotavirus dans le lait d'animaux transgéniques non-humains
ES2514316T3 (es) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Partículas similares a virus (VLPs) de Norovirus y Sapovirus
HUE033858T2 (en) * 2012-02-14 2018-01-29 Merial Inc Rotavirus unit vaccines and method for their preparation and use
EP2849779B1 (fr) * 2012-05-16 2021-01-06 Adelaide Research & Innovation Pty Ltd. Vaccin cellulaire et procédé d'induction d'une réponse immunitaire chez un sujet
WO2016115630A1 (fr) * 2015-01-23 2016-07-28 Medicago Inc. Production de particule de type rotavirus dans des plantes
CN108504718A (zh) * 2018-03-27 2018-09-07 东莞市第三人民医院 一种CaSR在RV、NSP4感染后的表达水平分析方法
CN117866858A (zh) * 2023-11-30 2024-04-12 吉林农业大学 一种表达猪轮状病毒抗原的重组植物乳杆菌及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5186933A (en) * 1986-12-30 1993-02-16 Baylor College Of Medicine Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system
US5298244A (en) * 1990-10-25 1994-03-29 University Of Saskatchewan Assembled viral particles and their use in a vaccine to rotaviral disease
US6210682B1 (en) * 1995-06-14 2001-04-03 Baylor College Of Medicine Rotavirus enterotoxin NSP4 and methods of using same
US6534067B1 (en) * 1999-10-14 2003-03-18 Baylor College Of Medicine Rotavirus enterotoxin adjuvant
FR2806087B1 (fr) * 2000-03-07 2002-10-18 Agronomique Inst Nat Rech Particules pseudovirales de rotavirus et leur utilisation pour vectoriser des proteines ou des acides nucleiques

Also Published As

Publication number Publication date
WO2002036172A3 (fr) 2002-09-19
EP1349571A2 (fr) 2003-10-08
EP1349571A4 (fr) 2005-02-16
WO2002036172A2 (fr) 2002-05-10
AU2002220025A1 (en) 2002-05-15

Similar Documents

Publication Publication Date Title
Dalsgaard et al. Plant–derived vaccine protects target animals against a viral disease
US5690938A (en) Oral immunization with multiple particulate antigen delivery system
US20220313812A1 (en) Senecavirus a immunogenic compositions and methods thereof
EP0546787A2 (fr) Expression d'immunogènes spécifiques utilisant des antigènes viraux
CA2627105A1 (fr) Vaccin antigrippal constitue d'antigenes combinatoires
KR20190110605A (ko) 돼지 코로나바이러스 백신
US6673355B1 (en) Rotavirus enterotoxin NSP4 and methods of using same
EP0661999B1 (fr) Vaccins destines a lutter contre le virus immunodeficitaire felin
NO341881B1 (no) Polypeptid, protein, metode for fremstilling av salmonid alphavirus nøytraliserende antistoffer, nukleinsyre, bærer, vaksine og diagnostisk sett
US20100034845A1 (en) Avian hepatitis e virus, vaccines and methods of protecting against avian hepatitis-splenomegaly syndrome and mammalian hepatitis e
JP2023544396A (ja) ロタウイルスに対するワクチン接種のために有用な融合タンパク質
JPH06504190A (ja) アセンブルしたウイルス粒子およびロタウイルス疾患ワクチンにおけるその使用
US6210682B1 (en) Rotavirus enterotoxin NSP4 and methods of using same
CA2427809A1 (fr) Enterotoxine nsp4 de rotavirus et ses methodes d'utilisation
US10456460B2 (en) Vaccine compositions for treatment of Zika virus
CA2982796C (fr) Compositions de vaccin destinees au traitement du virus zika
US20030175303A1 (en) Production method of recombinant rotavirus structural proteins and vaccine composition
AU768605B2 (en) Rotavirus enterotoxin NSP4 and methods of using same
US20240050555A1 (en) Immunogenic composition useful for vaccination against rotavirus
WO1989006971A1 (fr) Segments de genes de rotavirus conserves et utilisation de tels segments dans des techniques d'immunisation et de neutralisation
JP2023544403A (ja) サーコウイルス科カプシドタンパク質を含む融合タンパク質、及びそれから構成されるキメラウイルス様粒子
CN117959420A (zh) 一种猪流行性腹泻病毒二价亚单位疫苗及制备方法
Both et al. Analysis of Rotavirus Proteins by Gene Cloning, Mutagenesis, and Expression
Koci et al. Schultz-Cherry et al.
Ren Epitope mapping of the non-structural protein 2 (NSP2) of rotavirus

Legal Events

Date Code Title Description
FZDE Discontinued